2nd Quarter - Report — TARPLIN STRATEGIES LLC for GENENTECH, INC. (2011)

Firm

TARPLIN STRATEGIES LLC

Client

GENENTECH, INC.

Income

$75,000

Expenses

—

What was lobbied

4 issue areas, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

Public Law 111-148, the Patient Protection and Affordable Care Act - Implementation issues related to Medicare and Medicaid reimbursement for biotherapeutics, comparative effectiveness research, and FDA approval of follow-on biologics. Public Law 111-152, the Health Care and Education Reconciliation Act of 2010 - Implementation issues related to Medicare and Medicaid payment for biotherapeutics, the 340B program, and the Medicare drug benefit.

Lobbyist	Covered position, as disclosed
RICHARD JOSEPH TARPLIN	and Families

Contacted: HOUSE OF REPRESENTATIVES; Food & Drug Administration (FDA); SENATE; Executive Office of the President (EOP); Health & Human Services, Dept of (HHS); Centers For Medicare and Medicaid Services (CMS)

Pharmacy PHA

Public Law 111-148, the Patient Protection and Affordable Care Act - Implementation issues related to FDA approval of follow-on biologics and length of data exclusivity period, 340B drug pricing program, structure of the Medicare prescription drug benefit. Public Law 111-152, the Health Care and Education Reconciliation Act of 2010 - Implementation issues related to Medicare and Medicaid reimbursement, fees assessed on the pharmaceutical industry, design and structure of the Medicare prescription drug benefit. General issues and congressional oversight related to FDA approval and CMS coverage decisions regarding Avastin and Lucentis.

Lobbyist	Covered position, as disclosed
RICHARD JOSEPH TARPLIN	and Families

Contacted: Executive Office of the President (EOP); Food & Drug Administration (FDA); Centers For Medicare and Medicaid Services (CMS); SENATE; Health & Human Services, Dept of (HHS); HOUSE OF REPRESENTATIVES

Medicare/Medicaid MMM

Public Law 111-148, the Patient Protection and Affordable Care Act - Implementation issues related to Medicare and Medicaid reimbursement for biotherapeutics. Participated in discussions with House and Senate staff on Medicare coverage/payment issues related to cancer biotherapeutics, including Avastin and Lucentis.

Lobbyist	Covered position, as disclosed
RICHARD JOSEPH TARPLIN	and Families.

Contacted: Health & Human Services, Dept of (HHS); Centers For Medicare and Medicaid Services (CMS); HOUSE OF REPRESENTATIVES; SENATE; Food & Drug Administration (FDA); Executive Office of the President (EOP)

Medical/Disease Research/Clinical Labs MED

Public Law 111-148, the Patient Protection and Affordable Care Act of 2009 - Implementation issues related to the authorization for comparative effectiveness research and the the Patient-Centered Outcomes Research Institute.

Lobbyist	Covered position, as disclosed
RICHARD JOSEPH TARPLIN	and Families.

Contacted: HOUSE OF REPRESENTATIVES; SENATE; Food & Drug Administration (FDA); Executive Office of the President (EOP); Centers For Medicare and Medicaid Services (CMS); Health & Human Services, Dept of (HHS)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.